Analysis of efficacy obtained with a trivalent inactivatedserovars 4, 5, and 12 vaccine and commercial vaccines against Glässer's disease in piglets.

Abstract

The objective of this study was to assess the efficacy of a trivalent inactivatedserovars 4, 5, and 12 vaccine with polymeric adjuvant gel (GEL) and commercial vaccines against Glässer's disease in piglets. Commercial vaccines containing inactivatedserovars 4 and 5 (China), inactivatedserovars 1 and 6 (Spain), and inactivatedserovar 5 (USA) were also evaluated. Our results demonstrated that the trivalent inactivatedserovars 4, 5, and 12 vaccine with GEL adjuvant can provide better protection against the 3 most common pathogenic serovars circulating in China than other commercial vaccines tested. Our findings also indicated that inactivatedserovars 1 and 6 vaccine cross-protects piglets againstserovars 4 and 5; inactivatedserovar 5 vaccine cross-protects piglets againstserovar 4 challenge; but none of the commercial vaccines tested in this study protected piglets againstserovar 12. Our results provide a basis for further identification of common protective antigens that can induce cross-protection against heterogeneous serovars.